Figure 4.

Celecoxib and LY294002 synergistically inhibit the proliferation and migration of lung cancer cells. (A) HCC827 cells were cultured with the indicated concentrations of the PI3K inhibitor LY294002. Cell proliferation was assessed using a CCK-8 assay. LY294002 at a concentration of 10 µM significantly inhibits cell proliferation (**p < 0.01), whereas < 10 µM of LY294002 has no effect on cell proliferation. (B) HCC827 cells were pretreated with 5µM LY294002 or 10 µM of the COX-2 inhibitor celecoxib, which has no effect on cell proliferation as shown in Figure S3 or the combination of these two inhibitors for 1 h and subsequently cultured with PGE₂ for 72 h. The proliferation was evaluated using a CCK-8 kit. The combination of LY294002 and Celecoxib dramatically suppresses cell proliferation. The data are presented as the mean ± SD (n = 3, Student’s t-test; *p < 0.05, **p < 0.01, ***p < 0.001). The data represent at least three independent experiments. (C) The effect of LY294002 and Celecoxib on PGE₂-mediated cell migration was evaluated using a transwell assay. The combination of LY294002 and Celecoxib significantly reduces migratory capability of tumor cells. The data are presented as the mean ± SD (two-sided Student’s t-test, n = 3, ***P < 0.001). Blank indicates the cells that were not treated with PGE_2, LY294002 or Celecoxib.